AVIR

Atea Pharmaceuticals Inc. Common Stock (AVIR)

Stock · NASDAQ · Health Care

$4.33as of 10/16/2026

Price chart

Open in TradingView

Active signals

BOLL Breakdown63.9%200 SMA Touch49.0%
Resistance level
$5.35
Industry
Biotechnology: Pharmaceutical Preparations

AVIR Signal Track Record

How signals performed across all stocks →

What AVIR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike37-4.6%41%
Bollinger Band Breakout23-2.2%43%
Bollinger Band BreakdownActive now19+2.3%53%
200-Day Moving Average TouchActive now14+3.0%57%
Any 20-session window (baseline)-1.7%44%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-58…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
55

Fundamentals

1-day range
$4.3$4.55
Market cap
$399.34M
P/E (trailing)
—
P/E (forward)
-2.92
EPS (trailing)
$-2.09
Dividend yield
—
Beta
0.70
Avg. volume
303.0K
52-week range
$2.87$6.45
Next earnings: November 11, 2026 · EPS estimate $-0.50confirmed

How Atea Pharmaceuticals Inc. Common Stock Makes Money

Where the revenue actually goes — FY2021 annual results

market-wall.comTotalRevenue$351.37MNet Income$121.19M (34%)R&D$167.21M (48%)SG&A$45.78M (13%)Tax$17.40M (5%)AVIR

Source: 10-K filed Feb 28, 2022 · via SEC EDGAR / Finnhub

Operating Income$138.38M(39%)

Forecasts

3 analyst ratings

Buy 78%
Hold 22%
Sell 0%
1-year price forecast
High
$11.25
+159.8%
Median
$10
+130.9%
Low
$7
+61.7%

Atea Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • AVIR
    Atea Pharmaceuticals Inc. Common Stock
    $4.32
    ▼ 4.64%
    Market cap $399.34MP/E —
    $2.87$6.45
  • ABEO
    Abeona Therapeutics Inc. Common Stock
    $4.43
    ▼ 4.73%
    Market cap $393.27MP/E 5.50
    $4$7.65
  • ENTA
    Enanta Pharmaceuticals Inc. Common Stock
    $11.1
    ▼ 3.23%
    Market cap $387.91MP/E —
    $10.2$17.15
  • KMDA
    Kamada Ltd. Ordinary Shares
    $7.76
    ▼ 0.89%
    Market cap $411.88MP/E 20.30
    $6.55$9.35
  • RCKT
    Rocket Pharmaceuticals Inc. Common Stock
    $2.18
    ▼ 7.63%
    Market cap $386.55MP/E —
    $2.42$5.45
  • PBYI
    Puma Biotechnology Inc Common Stock
    $9.83
    ▼ 6.56%
    Market cap $413.30MP/E 20.62
    $4.58$10.5
  • ASMB
    Assembly Biosciences Inc. Common Stock
    $20.09
    ▼ 2.33%
    Market cap $420.36MP/E 333.50
    $19.98$39.71

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
478.1K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
58.19M
Total value held
$303.50M
Institutional holders
123
Top holders this quarter
  • Unknown11.95M
  • Unknown8.44M
  • Unknown7.06M
  • Unknown4.81M
  • Unknown3.25M
  • Unknown2.36M
  • Unknown1.86M
  • Unknown1.75M
  • Unknown1.69M
  • Unknown1.58M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.